Transmission/disequilibrium tests of androgen receptor and glutathione S‐transferase pi variants in prostate cancer families

Population‐based case‐control studies have found relationships between risk of prostate cancer and genetic polymorphisms in the CAG repeat and GGC repeat of the X‐linked androgen receptor gene (AR) as well as the autosomal gene coding for glutathione S‐transferase pi (GSTP1). This family‐based study...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 98; no. 6; pp. 938 - 942
Main Authors Ho, Gloria Y.F., Knapp, Michael, Freije, Diha, Nelson, William G., Smith, Jeffrey R., Carpten, John D., Bailey‐Wilson, Joan E., Beaty, Terri H., Petersen, Gloria, Xu, Jianfeng, Kamensky, Victor, Walsh, Patrick C., Isaacs, William B.
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 20.04.2002
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Population‐based case‐control studies have found relationships between risk of prostate cancer and genetic polymorphisms in the CAG repeat and GGC repeat of the X‐linked androgen receptor gene (AR) as well as the autosomal gene coding for glutathione S‐transferase pi (GSTP1). This family‐based study utilized the transmission disequilibrium test to examine whether there was evidence that these polymorphisms could account for familial aggregation of prostate cancer. Seventy‐nine North American pedigrees were studied. Most of these families had 3 or more affected first‐degree relatives. Genotype information was obtained on 578 individuals. The reconstruction combined transmission disequilibrium test (RC‐TDT) was used to test for linkage. There was no evidence of linkage to the CAG and GGC repeat sequences in the AR gene or the pentanucleotide (ATAAA) repeat in the GSTP1 gene when each allele was analyzed separately or when alleles were grouped by repeat length. Our findings do not support the hypothesis that familial clustering of prostate cancer in high‐risk families is attributable to these genetic variants. © 2002 Wiley‐Liss, Inc.
Bibliography:Fax: +718‐430‐3076
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.10290